Niche differentiation Pharmozyme’s focus on Taq Polymerase free from bacterial and animal DNA contamination and the new RNA extraction free EF1 SARS-CoV-2 Detection Kit CE marked positions the company as a source of high-purity reagents and rapid, compliant diagnostics—a compelling value proposition for labs seeking contamination-free enzymes and streamlined testing workflows.

Targeted customers The company operates in biotechnology research with small headcount, suggesting partnerships with research institutions, contract research laboratories, diagnostic developers, and early-stage biotech startups that need high-purity enzymes and rapid detection solutions.

Growth opportunities Revenue range indicates early-stage commercial traction with room to scale; potential sales expansion through OEM partnerships, reagent supply agreements, and collaboration with diagnostic manufacturers developing SARS-CoV-2 and other molecular testing pipelines.

Compliance leverage CE marking for in vitro diagnostics provides a regulatory handle to approach European labs and distributors, enabling accelerated entry strategies and co-marketing opportunities with regional players focused on compliant molecular diagnostics.

Digital and partnerships Existing tech stack including WordPress, Shopify, and cloud services suggests readiness for direct-to-lab e-commerce and digital outreach; leverage content marketing, distributor networks, and targeted campaigns to build awareness among small to mid-size labs and biotech startups.